<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281591</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-115</org_study_id>
    <nct_id>NCT02281591</nct_id>
  </id_info>
  <brief_title>Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine</brief_title>
  <official_title>Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine Following Oral Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, open-label, randomised study in four parallel groups of healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, open-label, randomised study in four parallel groups of healthy volunteers:
      Group 1 = 900 mg of eslicarbazepine acetate (ESL, BIA 2-093); Group 2 = 450 mg of
      S-licarbazepine plus 450 mg of R-licarbazepine; Group 3 = 450 mg of S-licarbazepine; Group 4
      = 450 mg of Rlicarbazepine. In each group, the study consisted of a single-dose period (Phase
      A) followed by a repeateddose period of 7 days of duration in which the investigational
      product was administered once daily (Phase B). The repeated-dose phase started 96 h post
      single-dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - the Maximum Plasma Concentration</measure>
    <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - the Time of Occurrence of Cmax</measure>
    <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity</measure>
    <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point</measure>
    <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>eslicarbazepine acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-licarbazepine R-licarbazepine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-licarbazepine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>450 mg of S-licarbazepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-licarbazepine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>450 mg of Rlicarbazepine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <description>Tablets containing 900 mg</description>
    <arm_group_label>eslicarbazepine acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-licarbazepine</intervention_name>
    <description>capsules containing 225 mg</description>
    <arm_group_label>S-licarbazepine R-licarbazepine</arm_group_label>
    <arm_group_label>S-licarbazepine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-licarbazepine</intervention_name>
    <description>capsules containing 225 mg</description>
    <arm_group_label>S-licarbazepine R-licarbazepine</arm_group_label>
    <arm_group_label>R-licarbazepine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female subjects aged between 18 and 45 years, inclusive.

          -  Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive.

          -  Subjects who were healthy as determined by pre-study medical history, physical
             examination, vital signs, neurological examination, and 12-lead ECG.

          -  Subjects who had clinical laboratory tests clinically acceptable at screening and
             admission.

          -  Subjects who had negative tests for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab at
             screening.

          -  Subjects who were negative for drugs of abuse and alcohol at screening and admission.

          -  Subjects who were non-smokers or who smoke &lt; 10 cigarettes or equivalent per day.

          -  Subjects who are able and willing to give written informed consent.

          -  (If female) She was not of childbearing potential by reason of surgery or, if of
             childbearing potential, she used one of the following methods of contraception: double
             barrier, intrauterine device or abstinence.

          -  (If female) She had a negative pregnancy test at screening and admission to Phase A.

        Exclusion Criteria:

          -  Subjects who did not conform to the above inclusion criteria, OR

          -  Subjects who had a clinically relevant history or presence of respiratory,
             gastrointestinal, renal, hepatic, haematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, endocrine, connective tissue diseases or disorders.

          -  Subjects who had a clinically relevant surgical history.

          -  Subjects who had a clinically relevant family history.

          -  Subjects who had a history of relevant atopy.

          -  Subjects who had a history of relevant drug hypersensitivity (especially carbamazepine
             or oxcarbazepine).

          -  Subjects who had a history of alcoholism or drug abuse.

          -  Subjects who consumed more than 14 units of alcohol a week.

          -  Subjects who had a significant infection or known inflammatory process on screening or
             admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scope International Life Sciences AG,</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <results_first_submitted>November 28, 2014</results_first_submitted>
  <results_first_submitted_qc>November 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2014</results_first_posted>
  <last_update_submitted>November 28, 2014</last_update_submitted>
  <last_update_submitted_qc>November 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eslicarbazepine Acetate</title>
          <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)
BIA 2-093: Tablets containing 900 mg</description>
        </group>
        <group group_id="P2">
          <title>S-licarbazepine R-licarbazepine</title>
          <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
S-licarbazepine: capsules containing 225 mg
R-licarbazepine: capsules containing 225 mg</description>
        </group>
        <group group_id="P3">
          <title>S-licarbazepine</title>
          <description>450 mg of S-licarbazepine
S-licarbazepine: capsules containing 225 mg</description>
        </group>
        <group group_id="P4">
          <title>R-licarbazepine</title>
          <description>450 mg of Rlicarbazepine
R-licarbazepine: capsules containing 225 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eslicarbazepine Acetate</title>
          <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)
BIA 2-093: Tablets containing 900 mg</description>
        </group>
        <group group_id="B2">
          <title>S-licarbazepine R-licarbazepine</title>
          <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
S-licarbazepine: capsules containing 225 mg
R-licarbazepine: capsules containing 225 mg</description>
        </group>
        <group group_id="B3">
          <title>S-licarbazepine</title>
          <description>450 mg of S-licarbazepine
S-licarbazepine: capsules containing 225 mg</description>
        </group>
        <group group_id="B4">
          <title>R-licarbazepine</title>
          <description>450 mg of Rlicarbazepine
R-licarbazepine: capsules containing 225 mg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - the Maximum Plasma Concentration</title>
        <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eslicarbazepine Acetate</title>
            <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)
BIA 2-093: Tablets containing 900 mg</description>
          </group>
          <group group_id="O2">
            <title>S-licarbazepine R-licarbazepine</title>
            <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
S-licarbazepine: capsules containing 225 mg
R-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O3">
            <title>S-licarbazepine</title>
            <description>450 mg of S-licarbazepine
S-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O4">
            <title>R-licarbazepine</title>
            <description>450 mg of Rlicarbazepine
R-licarbazepine: capsules containing 225 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - the Maximum Plasma Concentration</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (BIA 2-194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15809" spread="3183"/>
                    <measurement group_id="O2" value="10496" spread="1432"/>
                    <measurement group_id="O3" value="10364" spread="3352"/>
                    <measurement group_id="O4" value="437" spread="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (BIA 2-195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222" spread="68.4"/>
                    <measurement group_id="O2" value="8099" spread="1258"/>
                    <measurement group_id="O3" value="132" spread="29.6"/>
                    <measurement group_id="O4" value="6941" spread="1054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (Oxcarbazepine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="25.1"/>
                    <measurement group_id="O2" value="261" spread="53.5"/>
                    <measurement group_id="O3" value="92.8" spread="21.8"/>
                    <measurement group_id="O4" value="101" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - the Time of Occurrence of Cmax</title>
        <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eslicarbazepine Acetate</title>
            <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)
BIA 2-093: Tablets containing 900 mg</description>
          </group>
          <group group_id="O2">
            <title>S-licarbazepine R-licarbazepine</title>
            <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
S-licarbazepine: capsules containing 225 mg
R-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O3">
            <title>S-licarbazepine</title>
            <description>450 mg of S-licarbazepine
S-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O4">
            <title>R-licarbazepine</title>
            <description>450 mg of Rlicarbazepine
R-licarbazepine: capsules containing 225 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - the Time of Occurrence of Cmax</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax (BIA 2-194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.916"/>
                    <measurement group_id="O2" value="1.01" spread="0.320"/>
                    <measurement group_id="O3" value="0.965" spread="0.496"/>
                    <measurement group_id="O4" value="10.7" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tmax (BIA 2-195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="4.14"/>
                    <measurement group_id="O2" value="1.41" spread="0.320"/>
                    <measurement group_id="O3" value="11.7" spread="3.77"/>
                    <measurement group_id="O4" value="1.22" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tmax (Oxcarbazepine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="1.61"/>
                    <measurement group_id="O2" value="1.34" spread="0.354"/>
                    <measurement group_id="O3" value="1.36" spread="1.44"/>
                    <measurement group_id="O4" value="1.21" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity</title>
        <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eslicarbazepine Acetate</title>
            <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)
BIA 2-093: Tablets containing 900 mg</description>
          </group>
          <group group_id="O2">
            <title>S-licarbazepine R-licarbazepine</title>
            <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
S-licarbazepine: capsules containing 225 mg
R-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O3">
            <title>S-licarbazepine</title>
            <description>450 mg of S-licarbazepine
S-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O4">
            <title>R-licarbazepine</title>
            <description>450 mg of Rlicarbazepine
R-licarbazepine: capsules containing 225 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity</title>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-∞ (BIA 2-194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271191" spread="47416"/>
                    <measurement group_id="O2" value="201409" spread="37377"/>
                    <measurement group_id="O3" value="132724" spread="20175"/>
                    <measurement group_id="O4" value="11003" spread="4476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-∞ (BIA 2-195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8816" spread="2168"/>
                    <measurement group_id="O2" value="116884" spread="22425"/>
                    <measurement group_id="O3" value="5417" spread="824"/>
                    <measurement group_id="O4" value="66087" spread="16072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-∞ (Oxcarbazepine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3181" spread="1078"/>
                    <measurement group_id="O2" value="4726" spread="1163"/>
                    <measurement group_id="O3" value="2500" spread="1923"/>
                    <measurement group_id="O4" value="1073" spread="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point</title>
        <time_frame>Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eslicarbazepine Acetate</title>
            <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)
BIA 2-093: Tablets containing 900 mg</description>
          </group>
          <group group_id="O2">
            <title>S-licarbazepine R-licarbazepine</title>
            <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
S-licarbazepine: capsules containing 225 mg
R-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O3">
            <title>S-licarbazepine</title>
            <description>450 mg of S-licarbazepine
S-licarbazepine: capsules containing 225 mg</description>
          </group>
          <group group_id="O4">
            <title>R-licarbazepine</title>
            <description>450 mg of Rlicarbazepine
R-licarbazepine: capsules containing 225 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point</title>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-t (BIA 2-194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268045" spread="46861"/>
                    <measurement group_id="O2" value="198313" spread="38771"/>
                    <measurement group_id="O3" value="130147" spread="19326"/>
                    <measurement group_id="O4" value="9419" spread="4707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-t (BIA 2-195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6757" spread="2211"/>
                    <measurement group_id="O2" value="114635" spread="21741"/>
                    <measurement group_id="O3" value="3074" spread="1001"/>
                    <measurement group_id="O4" value="65203" spread="16161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-t (Oxcarbazepine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1947" spread="757"/>
                    <measurement group_id="O2" value="3401" spread="902"/>
                    <measurement group_id="O3" value="748" spread="308"/>
                    <measurement group_id="O4" value="422" spread="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Eslicarbazepine Acetate</title>
          <description>900mg of eslicarbazepine acetate (ESL, BIA 2-093)
BIA 2-093: Tablets containing 900 mg</description>
        </group>
        <group group_id="E2">
          <title>S-licarbazepine R-licarbazepine</title>
          <description>450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
S-licarbazepine: capsules containing 225 mg
R-licarbazepine: capsules containing 225 mg</description>
        </group>
        <group group_id="E3">
          <title>S-licarbazepine</title>
          <description>450 mg of S-licarbazepine
S-licarbazepine: capsules containing 225 mg</description>
        </group>
        <group group_id="E4">
          <title>R-licarbazepine</title>
          <description>450 mg of Rlicarbazepine
R-licarbazepine: capsules containing 225 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (5.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Numbness of tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paraesthesia lips</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paraesthesia tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hungry</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acroparaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Concentration loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Head pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Increased libido</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister of fingers, without mention of infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Herpes labialis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bulla dorsum manus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

